Johnson & Johnson CEO Joaquin Duato says the company has no plans to enter the obesity market, instead focusing on areas such as cancer. He says oncology remains one of J&J's core growth pillars, and highlights dementia as another major challenge for the healthcare industry.…
Johnson & Johnson (JNJ) News
Latest headlines that mention JNJ, newest first · each headline opens the original publisher
- Last price
- $256.48
- Day change
- -0.76%
- Next earnings
- 2026-10-13 BMO
JNJ headlines
last 30 daysDon't underestimate this healthcare giant.
Johnson & Johnson Chairman & CEO Joaquin Duato says artificial intelligence is a force multiplier and has to be embraced. He's on this week's episode of The David Rubenstein Show: Peer to Peer Conversations. This interview was recorded on June 16 in Washington. (Source:…
Even in a recession, there's strong demand for J&J's myriad of pharmaceutical and healthcare products.
Bank of America nearly doubled its peak sales estimate for one Johnson & Johnson drug ahead of the company's third-quarter earnings.
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.
Medtronic is following a strategy that has worked well for Johnson & Johnson.
This is not an exhaustive list.
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.
Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.
One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.
Also mentioned with JNJ
30dHeadlines that tag both tickers
JNJ news alerts
Get an alert by email or push when a new headline mentions JNJ.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.